Bariatric Sleeve GastrectomyNCT07806448
Impact of Asprosin and Neuregulin 4 on Metabolic Parameters, Anthropometric Indices and Body Composition After Laparoscopic Sleeve Gastrectomy
An observational study of Bariatric Sleeve Gastrectomy, run by General Committee of Teaching Hospitals and Institutes, Egypt at 1 site in Egypt.
Trial summary
Asprosin and neuregulin 4 (NRG4) sit on opposing arms of adipose endocrine physiology. Asprosin is a fasting-induced, white adipose-derived glucogenic and orexigenic hormone that rises with adiposity and insulin resistance. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Bariatric Sleeve Gastrectomy
- What is being tested?
- sleeve gastrectomy
- Type of treatment
- Surgery or procedure
- How many people
- 160 participants
- Where
- 1 siteEgypt
- Study dates
- 17 Jul 2025to 26 Aug 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Eligibility for surgery follows the 2022 American Society for Metabolic and Bariatric Surgery and International Federation for the Surgery of Obesity and Metabolic Disorders indications, which supersede the 1991 National Institutes of Health thresholds. Metabolic and bariatric surgery is indicated at a body mass index of at least 35 kg/m² regardless of the presence, absence or severity of obesity-related comorbidities, and should be considered at 30-34.9 kg/m² in the presence of metabolic disease. Ethnicity-adjusted thresholds are applied where relevant. Baseline phenotyping additionally records the components of the 2025 framework for clinical versus preclinical obesity for descriptive purposes; eligibility is determined by the 2022 indications.
Who may be able to join
- body mass index of at least 35 kg/m² regardless of the presence
- absence or severity of obesity-related comorbidities
- should be considered at 30-34.9 kg/m² in the presence of metabolic disease
Who cannot join
- revisional or emergency surgery
- type 1 diabetes or insulin-treated type 2 diabetes
- use within three months of a GLP-1 receptor agonist
- dual GIP/GLP-1 receptor agonist
- SGLT2 inhibitor or thiazolidinedione
- systemic corticosteroid or immunosuppressive therapy
Show all 16Show fewer
- chronic liver disease of non-metabolic aetiology or cirrhosis
- alcohol intake above 20 g/day in women or 30 g/day in men
- estimated glomerular filtration rate below 60 mL/min/1.73 m²
- FBN1-related connective tissue disorder
- active or recent malignancy
- untreated thyroid
- adrenal or gonadal disorder
- pregnancy or lactation
- any device precluding bioelectrical impedance analysis
- high-sensitivity C-reactive protein above 10 mg/L at baseline
Trial locations and contacts
1 site in 1 country.
Egypt1 site
The surgical department of Medical Research Institute Hospital, Alexandria University
Alexandria, 21531
About this study
Official title: The Impact of Asprosin and Neuregulin 4 on Metabolic Parameters, Anthropometric Indices and Body Composition After Laparoscopic Sleeve Gastrectomy: Protocol for a Prospective Longitudinal Cohort Study With a Non-obese Reference Group and a Nested Mixed-meal Sub-study (ASPEN-SG)
Asprosin and neuregulin 4 (NRG4) sit on opposing arms of adipose endocrine physiology. Asprosin is a fasting-induced, white adipose-derived glucogenic and orexigenic hormone that rises with adiposity and insulin resistance. NRG4 is a brown and beige adipose-derived, anti-lipogenic and hepatoprotective factor that falls with adiposity. Both have been examined separately after metabolic and bariatric surgery, but never in the same cohort, and existing surgical data cannot separate a weight-loss-dependent effect from an effect of the operation itself.
Objectives: To quantify the change in fasting serum asprosin and NRG4 over twelve months after laparoscopic sleeve gastrectomy (LSG); to determine whether those changes are associated with metabolic improvement independently of weight loss; and to characterise their relationship with anthropometric indices and body composition.
Read the detailed description
Adipose tissue is an endocrine organ whose secretory profile changes profoundly after metabolic and bariatric surgery. Two of its products have attracted attention for opposite reasons, and the relationship between them has never been examined in a surgical population.
Asprosin is the C-terminal cleavage product of profibrillin, encoded by the two terminal exons of FBN1 and released principally by white adipose tissue. Its discovery established it as a fasting-induced glucogenic hormone acting on the hepatocyte through a cyclic AMP-protein kinase A pathway. It was subsequently shown to cross the blood-brain barrier and activate orexigenic AgRP neurons, thereby stimulating appetite and adiposity accrual. Two receptors have been described: the olfactory receptor OLFR734 for the hepatic glucogenic arm and protein tyrosine phosphatase receptor delta for the central orexigenic arm. In humans, circulating asprosin is consistently higher in obesity, insulin resistance, type 2 diabetes and metabolic syndrome, and a meta-analysis across these conditions confirms the association. Interventions that reduce adiposity lower it.
Neuregulin 4 is an epidermal growth factor family ligand of ErbB4, enriched in brown and beige adipose tissue and secreted as an endocrine signal to the liver. It is reduced in rodent and human obesity and protects against hepatic steatosis by suppressing lipogenesis. Hepatic NRG4 signalling constitutes an endocrine checkpoint governing the transition from simple steatosis to steatohepatitis, NRG4 promotes systemic fuel oxidation and a favourable adipokine profile, and exercise induces adipose NRG4 through PPARγ, which then disrupts hepatic cGAS-STING inflammatory signaling. In humans, low circulating NRG4 is associated with metabolic syndrome, subclinical carotid disease and steatotic liver disease in adults and children. The literature is not unidirectional: elevated NRG4 has been reported in diabetes, a meta-analysis of observational studies found no overall case-control difference, and a study with paired hepatic transcriptomic profiling found no difference in steatotic liver disease. This heterogeneity is widely attributed to differences in commercial assay calibration and population, a point that directly shapes the analytical design of the present study.
Only three studies have examined either analyte after metabolic and bariatric surgery. Serum asprosin fell six months after surgery, and pre-operative asprosin was the single independent predictor of six-month excess weight loss. In sleeve gastrectomy, adipose-tissue asprosin was elevated relative to non-obese controls while pre-operative serum asprosin did not discriminate, yet serum asprosin still fell by six months. For NRG4, a single dedicated study found that circulating NRG4 rose during the early post-operative recovery phase, before substantial weight loss, and that Nrg4 knockout blunted the hepatic benefit of sleeve gastrectomy in rodents, establishing the rise as contributory rather than merely correlative.
Four gaps follow. First, the two hormones have never been co-measured in any surgical cohort, so the relationship between the falling glucogenic-orexigenic arm and the rising hepatoprotective arm is uncharacterised. Second, existing surgical data are confined to a pre-operative measurement and a single six-month measurement, which cannot separate a weight-loss-dependent effect from an early effect of the operation. Third, neither analyte has been related to quantified body composition after surgery, only to crude anthropometry. Fourth, post-prandial asprosin dynamics, the physiologically defining feature of the hormone, have never been examined before and after a bariatric operation.
ASPEN-SG is designed to address these gaps.
- Conditions
- Bariatric Sleeve Gastrectomy
- Being tested
- sleeve gastrectomy
- Keywords
- Asprosin, neuregulin 4, NRG4, adipose endocrine physiology, sleeve gastrectomy, metabolic and bariatric surgery, adipokines, body composition, insulin resistance
- Medical subject headings
- Arachnodactyly, Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
sleeve gastrectomyProcedure or surgery
Greater curvature devascularisation commences 4-6 cm proximal to the pylorus and extends to the angle of His with complete fundal mobilisation; gastric transection is performed over a 36-40 Fr calibration bougie; staple-line reinforcement policy.
| Study group | Role | What they receive |
|---|---|---|
| Surgical | Sleeve gastrectomy:
The operation is standard care, not a study intervention, but is standardised and documented because technical variation would otherwise contaminate the biomarker trajectory. Greater curvature devascularisation commences 4-6 cm proximal to the pylorus and extends to the angle of His with complete fundal mobilisation; gastric transection is performed over a 36-40 Fr calibration bougie; staple-line reinforcement policy, operative time, blood loss, resected specimen weight, conversion and length of stay are recorded for every case, and the operating surgeon is entered as a random effect in sensitivity analysis. Receives: Procedure: sleeve gastrectomy | |
| Reference | A concurrent non-obese reference group (n = 40) is sampled once to establish the local reference interval | |
| Evaluable | 30 evaluable sub-study pairs for a paired comparison |
What is being measured
The primary outcome is the main question the study is designed to answer.
log-transformed fasting serum asprosin and NRG4
within-participant change from baseline in log-transformed fasting serum asprosin and NRG4
Measured: 6 months
HOMA-IR
the association of the change from baseline in log-transformed fasting serum asprosin and NRG4 with the change in HOMA-IR, independently of percentage total weight loss.
The Formula: It multiplies fasting glucose by fasting insulin and divides by a constant (22.5 when glucose is in mmol/L, or 405 when in mg/dL).
Less than 1.0: Optimal insulin sensitivity (low resistance). 1.0 to 1.9: Normal range. 2.0 to 2.9: Early insulin resistance. 3.0 or higher: Moderate to significant insulin resistance, raising the risk for pre-diabetes or type 2 diabetes.
Measured: 6 months
Secondary outcomes (10)
early-phase change
within-participant change from baseline in log-transformed fasting serum asprosin and NRG4.
Measured: at day 7 and at 1 month
anthropometry
Weight is measured to 0.1 kg on a calibrated platform scale in the morning after the fasting draw. Waist and hip circumferences are the mean of three readings, with a fourth taken if the range exceeds 1 cm. Two trained observers perform all anthropometry; inter-observer reliability is established before enrolment and an intraclass correlation below 0.95 for any circumference requires retraining.
Measured: at day 7, 1 month, 3 months, 6 months and 12 months
body composition
Body composition is measured on a single InBody 120 segmental analyser (InBody Co. Ltd., Seoul, South Korea) for the entire study, the platform used in this group's published body-composition work, which preserves comparability with that cohort. Measurement is standardised to the morning, fasting, post-void state with no exercise for 12 hours, no alcohol for 24 hours, light clothing, bare feet, and the same room and device at every visit. Recorded variables are body fat mass and percentage, body muscle mass and percentage, fat-free mass, skeletal muscle mass, visceral fat, total, intracellular and extracellular water, and the derived fat mass index, fat-free mass index, skeletal muscle mass index and the proportion of weight lost as fat-free mass.
Measured: at day 7, 1 month, 3 months, 6 months and 12 months
TyG index
The Triglyceride-Glucose (TyG) index is a simple, reliable blood marker used to measure insulin resistance and cardiometabolic risk.
Normal and High-Risk Ranges:
Optimal: A TyG index under 4.49 (using specific standard scales) or lower values generally point to healthy metabolic function.
Insulin Resistance: Values above standard cutoffs (often varying by population, with high risk frequently cited at ≥ 8.77 or ≥ 9.04 depending on the specific diagnostic calibration) suggest the body is struggling to process insulin properly.
Measured: at day 7, 1 month, 3 months, 6 months and 12 months
lipid profile
A lipid profile is a blood test that measures the amount of cholesterol and fats in your blood to check your risk for heart disease.
Total Cholesterol: The overall amount of cholesterol in your blood. A normal level is below 200 mg/dL.LDL (Low-Density Lipoprotein): The "bad" cholesterol that can block your blood vessels. A normal level is below 100 mg/dL.HDL (High-Density Lipoprotein): The "good" cholesterol that helps clear bad cholesterol away. A higher level (above 60 mg/dL) protects your heart.Triglycerides: A type of fat stored for energy. A normal level is below 150 mg/dL.VLDL (Very Low-Density Lipoprotein): A type of bad fat that carries triglycerides. A normal level is below 30 mg/dL.
Measured: at day 7, 1 month, 3 months, 6 months and 12 months
AST/ALT ratio
The AST/ALT ratio (also called the De Ritis ratio) compares two liver enzymes in your blood to help doctors find the cause of liver or muscle damage.
Less than 1.0: ALT is higher than AST. This is common in metabolic fatty liver stress or viral hepatitis.
Around 1.0 to 1.2: AST and ALT are balanced or slightly raised together, which can happen with early liver stress or viral infections.
1.2 to 2.0: AST is higher than ALT. This can point to advanced liver scarring (fibrosis), cirrhosis, or recent intense exercise.
Greater than 2.0: AST is more than double ALT. This strongly suggests alcohol-related liver injury or alcoholic hepatitis.
Non-liver causes: Because AST is also found in heart and skeletal muscles, high AST (and a high ratio) can happen after severe muscle damage or a heart event.
Measured: at day 7, 1 month, 3 months, 6 months and 12 months
high-sensitivity C-reactive protein
hs-CRP (high-sensitivity C-reactive protein) is a blood test that measures low levels of inflammation in the body to help assess your risk of heart disease.
Results are measured in milligrams per liter (mg/L):
Low risk: Less than 1.0 mg/L Average or moderate risk: 1.0 to 3.0 mg/L High risk: Above 3.0 mg/L Very high (above 10 mg/L): Usually points to a current infection or acute injury rather than long-term heart risk.
Measured: at day 7, 1 month, 3 months, 6 months and 12 months
leptin
Leptin is a hormone made mostly by fat cells that helps your body manage energy balance and long-term appetite.
Males (Normal BMI): [0.5 to 12.5 nanograms per milliliter (ng/mL)](0.6.1, 0.6.2) Females (Normal BMI): [0.5 to 15.2 ng/mL](0.6.1, 0.6.2) (women often show higher levels than men at comparable body fat due to estrogen effects).
Obese Individuals (Any Sex): Typically range from 20 to 100+ ng/mL, which often reflects a leptin resistance pattern rather than simple excess.
Deficient Levels: Below 0.5 ng/mL can indicate true deficiency or severe malnutrition/over-dieting
Measured: at day 7, 1 month, 3 months, 6 months and 12 months
adiponectin
Adiponectin is a protective protein hormone secreted by fat tissue that helps regulate glucose levels, break down fatty acids, and lower systemic inflammation.
Normal Range: Typically ranges from 5 to 37 µg/mL depending on your body mass index (BMI) and sex.
Low Levels: Connected to obesity, type 2 diabetes, metabolic syndrome, and heart disease.
Measured: at day 7, 1 month, 3 months, 6 months and 12 months
ghrelin
Ghrelin is a peptide hormone produced mainly by the stomach that signals your brain to stimulate appetite and increase food intake.
The normal reference range for total ghrelin in plasma typically spans from 100 to 1,200 pg/mL in healthy adults, though specific values change based on whether you are fasting or have recently eaten:
Fasting state: Levels rise to stimulate hunger, often ranging between 500 and 2,500 pg/mL.
Postprandial state (after eating): Levels drop significantly, usually falling between 100 and 900 pg/mL.
Normal-weight controls: Specific reference panels often cite a baseline fasting range of 520 to 700 pg/mL.
Measured: at day 7, 1 month, 3 months, 6 months and 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Sep 2026
- Study start17 Jul 2025
- Primary completion17 Jul 2026
- Study completion26 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Bariatric Sleeve GastrectomyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 160 participants (actual)
Sponsor and investigators
- Lead sponsor
- General Committee of Teaching Hospitals and Institutes, Egypt
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Mohamed Hany Ashour, General Committee of Teaching Hospitals and Institutes, Egypt
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07806448
- Sponsor's protocol ID
- Asprosin and neuregulin 4
- Status last verified
- Sep 2026
- First submitted
- 1 Sep 2026
- Last updated
- 10 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Can be asked by the contact person
Study at a glance
From the registry record, last updated by the sponsor on 10 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Asprosin and Neuregulin 4 on Metabolic Parameters, Anthropometric Indices and Body Composition After Laparoscopic Sleeve Gastrectomy: Protocol for a Prospective Longitudinal Cohort Study With a Non-obese Reference Group and a Nested Mixed-meal Sub-study (ASPEN-SG)
- ClinicalTrials.gov ID
- NCT07806448
- Acronym / sponsor ID
- Asprosin and neuregulin 4
- Conditions
- Bariatric Sleeve Gastrectomy
- Keywords
- Asprosin, neuregulin 4, NRG4, adipose endocrine physiology, sleeve gastrectomy, metabolic and bariatric surgery, adipokines, body composition
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 160 participants (actual)
- Lead sponsor
- General Committee of Teaching Hospitals and Institutes, EgyptOther government
- Study start
- 17 Jul 2025 (actual)
- Primary completion
- 17 Jul 2026 (actual)
- Study completion
- 26 Aug 2026 (actual)
- First posted
- 8 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Asprosin and neuregulin 4 (NRG4) sit on opposing arms of adipose endocrine physiology. Asprosin is a fasting-induced, white adipose-derived glucogenic and orexigenic hormone that rises with adiposity and insulin resistance. NRG4 is a brown and beige adipose-derived, anti-lipogenic and hepatoprotective factor that falls with adiposity. Both have been examined separately after metabolic and bariatric surgery, but never in the same cohort, and existing surgical data cannot separate a weight-loss-dependent effect from an effect of the operation itself.
Objectives: To quantify the change in fasting serum asprosin and NRG4 over twelve months after laparoscopic sleeve gastrectomy (LSG); to determine whether those changes are associated with metabolic improvement independently of weight loss; and to characterise their relationship with anthropometric indices and body composition.
Detailed description
Adipose tissue is an endocrine organ whose secretory profile changes profoundly after metabolic and bariatric surgery. Two of its products have attracted attention for opposite reasons, and the relationship between them has never been examined in a surgical population.
Asprosin is the C-terminal cleavage product of profibrillin, encoded by the two terminal exons of FBN1 and released principally by white adipose tissue. Its discovery established it as a fasting-induced glucogenic hormone acting on the hepatocyte through a cyclic AMP-protein kinase A pathway. It was subsequently shown to cross the blood-brain barrier and activate orexigenic AgRP neurons, thereby stimulating appetite and adiposity accrual. Two receptors have been described: the olfactory receptor OLFR734 for the hepatic glucogenic arm and protein tyrosine phosphatase receptor delta for the central orexigenic arm. In humans, circulating asprosin is consistently higher in obesity, insulin resistance, type 2 diabetes and metabolic syndrome, and a meta-analysis across these conditions confirms the association. Interventions that reduce adiposity lower it.
Neuregulin 4 is an epidermal growth factor family ligand of ErbB4, enriched in brown and beige adipose tissue and secreted as an endocrine signal to the liver. It is reduced in rodent and human obesity and protects against hepatic steatosis by suppressing lipogenesis. Hepatic NRG4 signalling constitutes an endocrine checkpoint governing the transition from simple steatosis to steatohepatitis, NRG4 promotes systemic fuel oxidation and a favourable adipokine profile, and exercise induces adipose NRG4 through PPARγ, which then disrupts hepatic cGAS-STING inflammatory signaling. In humans, low circulating NRG4 is associated with metabolic syndrome, subclinical carotid disease and steatotic liver disease in adults and children. The literature is not unidirectional: elevated NRG4 has been reported in diabetes, a meta-analysis of observational studies found no overall case-control difference, and a study with paired hepatic transcriptomic profiling found no difference in steatotic liver disease. This heterogeneity is widely attributed to differences in commercial assay calibration and population, a point that directly shapes the analytical design of the present study.
Only three studies have examined either analyte after metabolic and bariatric surgery. Serum asprosin fell six months after surgery, and pre-operative asprosin was the single independent predictor of six-month excess weight loss. In sleeve gastrectomy, adipose-tissue asprosin was elevated relative to non-obese controls while pre-operative serum asprosin did not discriminate, yet serum asprosin still fell by six months. For NRG4, a single dedicated study found that circulating NRG4 rose during the early post-operative recovery phase, before substantial weight loss, and that Nrg4 knockout blunted the hepatic benefit of sleeve gastrectomy in rodents, establishing the rise as contributory rather than merely correlative.
Four gaps follow. First, the two hormones have never been co-measured in any surgical cohort, so the relationship between the falling glucogenic-orexigenic arm and the rising hepatoprotective arm is uncharacterised. Second, existing surgical data are confined to a pre-operative measurement and a single six-month measurement, which cannot separate a weight-loss-dependent effect from an early effect of the operation. Third, neither analyte has been related to quantified body composition after surgery, only to crude anthropometry. Fourth, post-prandial asprosin dynamics, the physiologically defining feature of the hormone, have never been examined before and after a bariatric operation.
ASPEN-SG is designed to address these gaps.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Surgical | – | Procedure: sleeve gastrectomySleeve gastrectomy: The operation is standard care, not a study intervention, but is standardised and documented because technical variation would otherwise contaminate the biomarker trajectory. Greater curvature devascularisation commences 4-6 cm proximal to the pylorus and extends to the angle of His with complete fundal mobilisation; gastric transection is performed over a 36-40 Fr calibration bougie; staple-line reinforcement policy, operative time, blood loss, resected specimen weight, conversion and length of stay are recorded for every case, and the operating surgeon is entered as a random effect in sensitivity analysis. |
| Reference | – | –A concurrent non-obese reference group (n = 40) is sampled once to establish the local reference interval |
| Evaluable | – | –30 evaluable sub-study pairs for a paired comparison |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Eligibility for surgery follows the 2022 American Society for Metabolic and Bariatric Surgery and International Federation for the Surgery of Obesity and Metabolic Disorders indications, which supersede the 1991 National Institutes of Health thresholds. Metabolic and bariatric surgery is indicated at a body mass index of at least 35 kg/m² regardless of the presence, absence or severity of obesity-related comorbidities, and should be considered at 30-34.9 kg/m² in the presence of metabolic disease. Ethnicity-adjusted thresholds are applied where relevant. Baseline phenotyping additionally records the components of the 2025 framework for clinical versus preclinical obesity for descriptive purposes; eligibility is determined by the 2022 indications.
Key inclusion criteria (3 listed)
- body mass index of at least 35 kg/m² regardless of the presence
- absence or severity of obesity-related comorbidities
- should be considered at 30-34.9 kg/m² in the presence of metabolic disease
Key exclusion criteria (16 listed)
- revisional or emergency surgery
- type 1 diabetes or insulin-treated type 2 diabetes
- use within three months of a GLP-1 receptor agonist
- dual GIP/GLP-1 receptor agonist
- SGLT2 inhibitor or thiazolidinedione
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| sleeve gastrectomyGreater curvature devascularisation commences 4-6 cm proximal to the pylorus and extends to the angle of His with complete fundal mobilisation; gastric transection is performed over a 36-40 Fr calibration bougie; staple-line reinforcement policy. | Procedure or surgery | Surgical |
Primary outcome
log-transformed fasting serum asprosin and NRG4
Time frame: 6 months
within-participant change from baseline in log-transformed fasting serum asprosin and NRG4
HOMA-IR
Time frame: 6 months
the association of the change from baseline in log-transformed fasting serum asprosin and NRG4 with the change in HOMA-IR, independently of percentage total weight loss. The Formula: It multiplies fasting glucose by fasting insulin and divides by a constant (22.5 when glucose is in mmol/L, or 405 when in mg/dL). Less than 1.0: Optimal insulin sensitivity (low resistance). 1.0 to 1.9: Normal range. 2.0 to 2.9: Early insulin resistance. 3.0 or higher: Moderate to significant insulin resistance, raising the risk for pre-diabetes or type 2 diabetes.
10 secondary outcomes
early-phase change
Time frame: at day 7 and at 1 month
anthropometry
Time frame: at day 7, 1 month, 3 months, 6 months and 12 months
body composition
Time frame: at day 7, 1 month, 3 months, 6 months and 12 months
TyG index
Time frame: at day 7, 1 month, 3 months, 6 months and 12 months
lipid profile
Time frame: at day 7, 1 month, 3 months, 6 months and 12 months
AST/ALT ratio
Time frame: at day 7, 1 month, 3 months, 6 months and 12 months
high-sensitivity C-reactive protein
Time frame: at day 7, 1 month, 3 months, 6 months and 12 months
leptin
Time frame: at day 7, 1 month, 3 months, 6 months and 12 months
adiponectin
Time frame: at day 7, 1 month, 3 months, 6 months and 12 months
ghrelin
Time frame: at day 7, 1 month, 3 months, 6 months and 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Sep 2026.
- Individual participant dataSharing planned: Yes. Can be asked by the contact person
Related trials for Bariatric Sleeve Gastrectomy
Not yet recruitingObservational study
Serum Estradiol and Endometrial Thickness After Bariatric Surgery in Postmenopausal Women With Obesity
Obesity, Morbid, Postmenopause
RecruitingPhase 4
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
Liver Cirrhoses, Portal Hypertension Related to Cirrhosis
Recruiting
HUGO-SLEEVE: Evaluating the Feasibility of Robotic Sleeve Gastrectomy With a New Platform
Obesity (BMI > 35), Obesity (BMI > 35) and Diabetes Mellitus
RecruitingObservational study
15-years Outcomes of Sleeve Gastrectomy on Weight Loss
Bariatric Surgery, Sleeve Gastrectomy
Recruiting
Identification of Pre-surgical Phenotypic Indicators Predictive of Quality of Life Trajectories in Obese Patients Following Bariatric Surgery
Obesity, Morbid, Obesity and Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Bariatric Sleeve Gastrectomy, run by General Committee of Teaching Hospitals and Institutes, Egypt at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
log-transformed fasting serum asprosin and NRG4 (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Sep 2026.